Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 20;25(1):65-68.
doi: 10.3760/cma.j.issn.1007-3418.2017.01.019.

[Umbilical cord mesenchymal stem cells and their association with liver fibrosis]

[Article in Chinese]
L Tuo  1 , W Z Zeng  2 , H L Xue  2 , X L Wu  1
Affiliations
Review

[Umbilical cord mesenchymal stem cells and their association with liver fibrosis]

[Article in Chinese]
L Tuo et al. Zhonghua Gan Zang Bing Za Zhi. .

Abstract
in English, Chinese

At present, the most effective therapeutic method for end-stage liver fibrosis is liver transplantation. However, the application of liver transplantation is limited by a shortage of liver donors, a high incidence rate of surgical complications, graft-versus-host disease, and high medical costs. Umbilical cord mesenchymal stem cell (UC-MSC) transplantation may become a promising method for the treatment of liver diseases. UC-MSCs are adult stem cells which exhibit multipotential differentiation and can differentiate into hepatic parenchymal cells. Due to their functions including immune regulation and secretion of trophic factors, UC-MSCs can inhibit immune response, promote hepatocyte regeneration, alleviate the progression of liver fibrosis, and improve liver function. In addition, compared with bone marrow mesenchymal stem cells, UC-MSCs have abundant sources, noninvasive collection, and high safety and thus they are attracting more and more attention. This article reviews the characteristics of UC-MSCs and their mechanism of action in the treatment of liver fibrosis, as well as risks of UC-MSCs therapy.

当前对于终末期肝纤维化的最有效治疗手段为肝脏移植，但由于供体缺乏、手术相关并发症发生率高、抗宿主反应、医疗花费高等缺点，应用范围有限。而脐带间充质干细胞移植可作为治疗肝脏疾病的一类极具希望的治疗手段。脐带间充质干细胞是一类具有多向分化潜能的成体干细胞，能够定向分化为肝实质细胞，并且具有免疫调节、营养因子分泌等功能，因此，能够抑制免疫反应、促进肝细胞再生、缓解肝纤维化进展以及提升肝功能。另外，与骨髓间充质干细胞相比，脐带间充质干细胞来源丰富、收集过程无创、安全性较高，越来越多地引起了人们的关注。现对近年来脐带间充质干细胞的特性以及其治疗肝纤维化的机制和应用情况进行综述，并对相关风险进行了探讨。.

Keywords: Liver fibrosis; Therapeutics; Umbilical cord mesenchymal stem cells.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by